Trending Now
Free Weekly Newsletter.
We've been publishing our newsletter since 1998, and have had our share of huge winners including Immunomedics (IMMU) $3.00 to $86.00 (2016-2020). So sign up, it's free, and see what else we can come up with!
ALL NEWS
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's approaching $2 billion after some 'dilution,' which didn't prevent it...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market cap, addressing solutions which reach well over $1 billion. ...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is gone - oh Pshaw with them!
Novavax...
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days for those who went on to receive their...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we follow, shows a spike in either price or volume while...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
We're adding Citius Pharma to the Watch List, on the...
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines
ATLANTA,...
Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics.
Group includes leading...
Major Mpox Outbreak in the Democratic Republic of Congo.
As Reported in NPR's Gates and Soda
Major Mpox Outbreak in the Democratic Republic of Congo is a Worry to Disease docs.
UPDATED APRIL 2,...
Mpox Infections Rise to Almost Double Last Year’s Numbers.
The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of 2023.
The most recent data from the...
Adding Asia Broadband (AABB) to Speculative Watch List.
Asia Broadband, Gold Play With Digital Currency (NFT) Twist
The last speculative stock trading under $0.05, that we added to the Watch List was Pharamather (PHRRF), which traded...
GeoVax to Present at World Vaccine Congress, Thursday April 4th.
Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00 pm ET.
Post Reverse Split, Tharimmune (THAR) Announces Positive Phase I Results.
This is a story of 're-purposed' FDA approved drug, from drug overdose, to a solution for unrelenting itching. If approved, it can provide a much needed relief from what is described as...
Trump’s (DJT) up 48% Today
LIVE QUOTE
Our only thought is it would be a great idea, to give some of the stock to E Jean Carroll for her...
Adding Asia Broadband (AABB) to Speculative Watch List.
Asia Broadband, Gold Play With Digital Currency (NFT) Twist
The last speculative stock trading under $0.05, that we added to the Watch List was Pharamather (PHRRF), which traded...
Trump’s (DJT) up 48% Today
LIVE QUOTE
Our only thought is it would be a great idea, to give some of the stock to E Jean Carroll for her...
Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.
Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00.
(All Report Archive)
December 27th, 2023. Litchfield...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
MIAMI BEACH, FL / ACCESSWIRE / December 20,...
Continued Strength at LQR House (LQR) Post-Reverse Split.
Like a Surprise Christmas Gift, LQR House has Gained Nearly Four-Fold (330%) Post Split. New Report out Tomorrow.
LIVE QUOTE
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
IPOS
Another Look at the Snowflake (SNOW) Mega IPO.
We haven't looked at Snowflake (SNOW) since its amazing IPO debut. It was priced at $120 and opened for trading at $245...
conference calls
Nautilus (NLS) $8.50, Numbers Out. Time to go Bottom Fishing?
Adding Nautilus to the Watch List. Conference Call Transcript Below
New Street Targets at $15 per Share.
Most popular
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Innovus (INNV) in Silicon Review Interview.
POISED FOR INNOVATION.
The Silicon Review is the world’s most trusted online and print community for business &...
IMAC Holdings (BACK) Explodes 94% Higher Post Reverse Split, With 42 Million Shares Trading...
Simply Incredible! 2024 Will be the Year of Post Reverse Split Revenge!
Taking advantage of post reverse-split investor...
Aphex BioCleanse Hand Sanitizer Seeking FDA GRAS Approval.
Aphex BioCleanse Systems Enters Agreement with Now Biopharma for Hand Sanitizer Clinical Trial
PITTSFORD, N.Y., Aug. 31, 2020 /PRNewswire/ -- Aphex...